Partnerships and co-selling: examples that actually work in 2026 for healthcare and life sciences in the Middle East

This edition of the Growth Broker playbook is written for commercial leaders at healthtech, medtech, and life-sciences companies operating in the Middle East. In this market, Middle Eastern buyers reward in-person credibility, sovereign fit, and patient sequencing, so the way you install partnerships and co-selling has to be shaped to that reality from day one.

Most articles on partnerships and co-selling are five years out of date. This one is not. Partnerships and co-selling in 2026 is using another company's distribution to reach buyers you cannot cost-effectively reach yourself, and the examples below are all inside the last four quarters.

Example one: a Series B infrastructure company applied partnerships and co-selling to a list of 340 accounts and moved sourced and influenced pipeline from partners from a baseline to a defensible weekly number inside seven weeks. What worked was ruthless focus on trigger quality.

Example two: a bootstrapped agency owner ran the same play at one-tenth the budget and produced enough qualified pipeline to hire two full-time operators. The lesson is that partnerships and co-selling scales down, not just up.

Inside healthcare and life sciences, the binding constraint is almost always regulated-sale cycle length, not intent, and in the Middle East it is compounded by the fact that senior-relationship access, not product is what actually gates growth. Partnerships and co-selling is only useful here when it is pointed at both constraints at once.

Example three: an enterprise incumbent tried partnerships and co-selling across four regions in parallel and stalled — the exact pattern of signing MOUs no one operationalises. They restarted with one BU, hit the number in nine weeks, and then expanded.

The pattern across every winning example: they respect that one great partner is worth ten marketing hires, and they refuse to touch the model until they have a legible number on sourced and influenced pipeline from partners.

The pattern across every failing example: too many tools, too many stakeholders, no single owner. Fix that first and copy the plays.

If you take one thing from this list, it is that partnerships and co-selling is a discipline before it is a technology. The examples that work are all built on the same operating rhythm.

Concretely for healthcare and life sciences in the Middle East: the healthcare teams that install this get past procurement instead of dying in it, and one sovereign or family-office win in the Middle East justifies a full year of program spend. That is the reason it is worth installing partnerships and co-selling deliberately for this market rather than importing a playbook designed for somewhere else.